Neil Reithinger: Sure. We — when we collect receivables, potentially, yes, we pay debt — some debt. But moreover, it’s — as you heard from our inflection point we are at with our loss for the quarter, it’s $627,000. We are at that point where we want to keep feeding our growth and scalability. So we will be very selective about how we are going to use that outside of working capital, to use and to pay down debt, that will obviously be dependent on other potential capital raising initiatives that are needed to do that when loans come due, potentially if they could be extended. So we want to be very careful about the deployment of capital based on now becoming — given the inflection point we are at, knowing that we want to make sure we continue to scale with this next phase of our evolution, okay?
So — and we always — and we are — as far as from an AR standpoint itself, I mean, obviously, it’s a very — it’s a balance sheet account that all companies monitor very careful based on the economic environment, same thing with us. A lot of our clients are very — customers are very progressive and growing as well. So there every company likewise is affected by the market conditions. But we keep — obviously monitor that very closely, especially too, with regards to revenue and revenue recognition. So we believe we will be successful in our AR collection efforts and there are some balances that may extend the on and we work with those customers. But, so far, everything is within a time period that we think we are going to collect. But we are — back to — we will be very careful about the deployment of that to make sure we scale back operations for growth, okay.
Unidentified Analyst: Excellent. Thank you. And just a follow-up question, so I think all of us who are running businesses, we all understand that the economy has changed a lot and this word of self-sustainability, I think, is very important. So I also understand that Orgenesis is a growth company. So what’s the current thinking model right now, would — for the next few quarters, do we hope to operate on a breakeven level or some months we are still okay having some losses because we are still in a growth phase?
Vered Caplan: So, I think, on the services side, I mean, we are still going, right? I mean we were committed to use that capital. We got focus that idea. We want to maintain growth and that’s kind of part of our business plan. And as for the other side of the business, well, we really try to leverage as much as possible on grants and partnerships. We do have some commitments, but we are trying to keep them balanced as much as we can, because obviously, this is not the easiest time to collect capital.
Unidentified Analyst: Got it. Got it. And also I think this is going to be a very difficult question, but I am not sure if, because Orgenesis right now is really a disruptive business, providing new technologies and we do not know what the possible profit margin that this company could produce, let’s say, three years, four year, five years later when this is at a steady state, but perhaps, no longer a growth phase. Is there any range of margins — profit margins you think it’s possible for Orgenesis to achieve?
Vered Caplan: Look, we try to base our revenue on at least 50% gross profit, that’s what we guided to at least and around 20%, 25% EBITDA on our services. When you deal with out-licensing of therapy, well, that is a completely different model, right? I mean, you are just waiting for the upside. So that’s our goal. We have — as you can see from my finance — our financials, we try to maintain that. That’s kind of been our focus.
Unidentified Analyst: Got it. Got it. Yeah. Can I just squeeze in one last question, because I thought that fourth quarter was a very nice ramp-up in revenue, but we — if we do a year-to-year comparison, it’s sort of flattish, but for the coming next few quarters, where are we seeing ourselves in terms of the demand for OMPULs or even the services that we are providing?
